THE REASONS FOR CHOOSING 1-Shot

The comfort choice

- **SUPLASYN**® is commonly efficient with only 1 INJECTION (1)
- **UP TO 6 MONTH** clinical effect on pain and functionality (1)
- **OPTIMUM MOLECULAR WEIGHT**: optimum stimulation of endogenous Hyaluronic Acid synthesis & easy access to diseased tissue (1)
- **EASY** for doctors to inject (low viscosity)
- **Very good TOLERABILITY** (1)

Suitable for larger synovial joints

*This depends on the patient’s individual response


*This depends on the patient’s condition
ADVANTAGES OF ONLY 1 INJECTION

- REDUCTION OF THE COST OF TREATMENT
- PATIENT COMPLIANCE
- TIME SAVING
- VERY GOOD TOLERABILITY
- 98% NO ADVERSE EVENTS
- Can be safer than some other HAs

RESULTS AFTER 1 INJECTION OF SUPLASYN® 1-SHOT ONLY AT MONTH 3 AND 6

- Significant improvement in functionality: +34.9%*
- Results after 1 injection of SUPLASYN® 1-Shot only at month 3 and 6
- Significant decrease in pain scores compared to the VAS as measured by the patient at 3 and 6 months after SUPLASYN® 1-Shot injection

PATIENT SATISFACTION AT MONTH 3

- 86.7% of patients declared an improvement in their health

PATIENT SATISFACTION AT MONTH 6

- 88% of patients would repeat the treatment with SUPLASYN® 1-Shot

SUPLASYN® 1-SHOT: STERILE SODIUM HYALURONATE SOLUTION

HYALURONIC ACID (HA) is a normal component of the synovia and plays a central role in maintaining the physiological internal environment of the joint.

COMPOSITION: Viscosuplus solution of a defined molecular weight of purified hyaluronic acid, produced by fermentation.

Each syringe contains:

- Hyaluronic acid sodium salt
- Excipients q.s

PROPERTIES: Synergistic action of a proteolytic enzyme derived from the proteoglycan chains, the important components of all extracellular tissue structures, including cartilage and synovial fluid. The active substance of SUPLASYN® is a hyaluronic acid of defined molecular weight and with a high degree of purity.

INDICATIONS: SUPLASYN® is indicated for the symptomatic treatment of osteoarthritis. SUPLASYN® has been shown to be beneficial in osteoarthritis for the management of pain and improvement in physical function of joints. More than one joint may be treated at the same time.

DOSE AND ADMINISTRATION: Depending upon joint size, up to 6 ml may be administered intra-articularly. SUPLASYN® is the recommended schedule for SUPLASYN® supplied in a 2ml syringe is a 1 injection per week for 3 months, but up to 8 may be given depending on patient's condition. SUPLASYN® is intended for single administration. Use strict aseptic technique. Discard any unused portion of the syringe. The introduction of SUPLASYN® into the synovial space will assist in the normalisation of the joint following arthrophy.

CONTRAINDICATIONS/REPELATIONS: Do not administer to patients with known hypersensitivity reactions. Respect usual precautions and contraindications for any intra-articular injection. Do not inject intra-vascularly. SUPLASYN should not be used in patients presenting an inflammation/irritation of the joint, since adverse events more commonly occur in patients with already existing joint inflammation/irritation. As no clinical evidence is available on its use in children, pregnant or lactating women, treatment with SUPLASYN® is not recommended in these patients. The patient should rest 24-48 hours after the injection and avoid any strenuous activity over the full course of the treatment. Transient short duration pain may occur following intra-articular introduction. The affected joint may show a mild local reaction; pain, feeling of heat, hyperaemia, redness, irritation, or swelling/irritation. If these symptoms occur, the affected joint and apply ice locally. If these symptoms persist or worsen, discontinue use of SUPLASYN® and inform the physician. In such cases, a therapeutic intervention could be necessary, e.g. aspiration of joint fluid. Localised and more severe adverse events more commonly occur in patients with already existing joint inflammation/irritation. If these symptoms occur, the affected joint and apply ice locally. If these symptoms persist or worsen, discontinue use of SUPLASYN® and inform the physician. In such cases, a therapeutic intervention could be necessary, e.g. aspiration of joint fluid. Localised and more severe adverse events could be accompanied by systemic reactions such as fever, chills, or cardiovascular reactions, and in rare cases anaphylactic reactions. In extremely rare circumstances, redness, urticaria, synovitis, and a drop in blood pressure have been reported following the administration of SUPLASYN®. Discontinue use if adverse reactions are experienced. Avoid using SUPLASYN® with aseptic or aseptic agents containing quaternary ammonium salts solutions.

WARNING: KEEP OUT OF REACH OF CHILDREN. DO NOT USE IF BLOOD IS DAMAGED. TO BE USED BY A PHYSICIAN ONLY FOR SINGLE USE ONLY. DISCARD UNUSED PORTION OF SYRINGE. REUSE MAY CREATE A RISK OF CONTAMINATION AND/OR CAUSE PATIENT INFECTION OR CROSS INFECTION.

PACKAGING: Available in 2ml or 6ml syringes.

STORAGE: Store between 4°C and 25°C. DO NOT FREEZE. Bring to room temperature before injection.